Phreesia, Inc.

NYSE:PHR Rapporto sulle azioni

Cap. di mercato: US$1.3b

Phreesia Gestione

Gestione criteri di controllo 2/4

Phreesia Il CEO è Chaim Indig, nominato in Jan2005, e ha un mandato di 19.83 anni. la retribuzione annua totale è $ 8.27M, composta da 6% di stipendio e 94% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 2.25% delle azioni della società, per un valore di $ 28.16M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.8 anni e 17.1 anni.

Informazioni chiave

Chaim Indig

Amministratore delegato

US$8.3m

Compenso totale

Percentuale dello stipendio del CEO6.0%
Mandato del CEO19.8yrs
Proprietà del CEO2.2%
Durata media del management3.8yrs
Durata media del Consiglio di amministrazione17.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

Market Participants Recognise Phreesia, Inc.'s (NYSE:PHR) Revenues

Nov 07
Market Participants Recognise Phreesia, Inc.'s (NYSE:PHR) Revenues

Is Phreesia (NYSE:PHR) Weighed On By Its Debt Load?

Oct 08
Is Phreesia (NYSE:PHR) Weighed On By Its Debt Load?

Here's What Analysts Are Forecasting For Phreesia, Inc. (NYSE:PHR) After Its Second-Quarter Results

Sep 06
Here's What Analysts Are Forecasting For Phreesia, Inc. (NYSE:PHR) After Its Second-Quarter Results

Phreesia: Remain Bullish Given The Healthy Growth Outlook

Sep 05

Market Participants Recognise Phreesia, Inc.'s (NYSE:PHR) Revenues Pushing Shares 26% Higher

Jul 18
Market Participants Recognise Phreesia, Inc.'s (NYSE:PHR) Revenues Pushing Shares 26% Higher

Phreesia: Growth Remains Strong, With EBITDA Margin Set To Improve

Jun 06

The Price Is Right For Phreesia, Inc. (NYSE:PHR)

May 25
The Price Is Right For Phreesia, Inc. (NYSE:PHR)

Are Investors Undervaluing Phreesia, Inc. (NYSE:PHR) By 39%?

May 03
Are Investors Undervaluing Phreesia, Inc. (NYSE:PHR) By 39%?

At US$23.80, Is Phreesia, Inc. (NYSE:PHR) Worth Looking At Closely?

Apr 12
At US$23.80, Is Phreesia, Inc. (NYSE:PHR) Worth Looking At Closely?

Phreesia Continues To Stay Positive On The Business Growth

Apr 03

Phreesia: Healthcare Digitization Beneficiary Hampered By Valuation

Mar 01

Investors Still Waiting For A Pull Back In Phreesia, Inc. (NYSE:PHR)

Feb 16
Investors Still Waiting For A Pull Back In Phreesia, Inc. (NYSE:PHR)

Phreesia: Remain Buy Rated As The Business Pivot Towards Profitable Growth

Jan 04

Is Phreesia Finally Turning The Corner?

Dec 07

Does Phreesia (NYSE:PHR) Have A Healthy Balance Sheet?

Oct 25
Does Phreesia (NYSE:PHR) Have A Healthy Balance Sheet?

Phreesia: Share Price Dip Is A Buying Opportunity

Sep 21

Phreesia: Strong Execution Should Continue To Drive Growth

Jul 11

Phreesia, Inc.'s (NYSE:PHR) Share Price Matching Investor Opinion

May 18
Phreesia, Inc.'s (NYSE:PHR) Share Price Matching Investor Opinion

Phreesia: Strong Growth Momentum With Expanded TAM

Jan 28

Phreesia - Healthcare Ecosystem At An Attractive Valuation

Dec 13

Phreesia Q3 2023 Earnings Preview

Dec 07

Phreesia GAAP EPS of -$0.89 beats by $0.08, revenue of $67.9M beats by $2.15M

Sep 07

Phreesia: Their Time Has Passed

May 10

Opportunistic Time To Buy Phreesia's Healthcare Disruption

Dec 27

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Chaim Indig rispetto agli utili di Phreesia?
DataCompenso totaleStipendioGuadagni aziendali
Jul 31 2024n/an/a

-US$100m

Apr 30 2024n/an/a

-US$119m

Jan 31 2024US$8mUS$495k

-US$137m

Oct 31 2023n/an/a

-US$144m

Jul 31 2023n/an/a

-US$152m

Apr 30 2023n/an/a

-US$162m

Jan 31 2023US$8mUS$515k

-US$176m

Oct 31 2022n/an/a

-US$185m

Jul 31 2022n/an/a

-US$181m

Apr 30 2022n/an/a

-US$158m

Jan 31 2022US$9mUS$515k

-US$118m

Oct 31 2021n/an/a

-US$80m

Jul 31 2021n/an/a

-US$50m

Apr 30 2021n/an/a

-US$32m

Jan 31 2021US$6mUS$419k

-US$27m

Oct 31 2020n/an/a

-US$23m

Jul 31 2020n/an/a

-US$19m

Apr 30 2020n/an/a

-US$83m

Jan 31 2020US$10mUS$346k

-US$91m

Oct 31 2019n/an/a

-US$102m

Jul 31 2019n/an/a

-US$113m

Apr 30 2019n/an/a

-US$54m

Jan 31 2019US$510kUS$300k

-US$45m

Compensazione vs Mercato: La retribuzione totale di Chaim ($USD 8.27M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 5.33M ).

Compensazione vs guadagni: La retribuzione di Chaim è aumentata nonostante l'azienda non sia redditizia.


AMMINISTRATORE DELEGATO

Chaim Indig (44 yo)

19.8yrs

Mandato

US$8,273,307

Compensazione

Mr. Chaim Indig co-founded Phreesia, Inc. in January 2005 and serves as Chief Executive Officer and Director since January 2005. Mr. Indig has helped to revolutionize the patient check-in experience. Under...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Chaim Indig
Co-Founder19.8yrsUS$8.27m2.25%
$ 28.2m
Evan Roberts
Co-Founder & COO19.8yrsUS$4.50m1.3%
$ 16.3m
Balaji Gandhi
Chief Financial Officer1.7yrsUS$5.91m0.17%
$ 2.1m
Allison Hoffman
General Counsel & Secretary4.3yrsUS$3.04m0.082%
$ 1.0m
David Linetsky
Senior Vice President of Life Sciences5.7yrsUS$4.47m0.36%
$ 4.5m
Yvonne Hui
VP & Principal Accounting Officerless than a yearNessun datoNessun dato
Jack Callahan
Chief Technology Officerless than a yearNessun datoNessun dato
Maureen McKinney
Vice President of Corporate Communications3.8yrsNessun datoNessun dato
Ashwin Uttamchandani
Vice President of Sales & Marketing Operationsno dataNessun datoNessun dato
Amy VanDuyn
Senior Vice President of Human Resources14.6yrsNessun dato0.21%
$ 2.6m
Hilary Hatch
Chief Clinical Officer3.6yrsNessun datoNessun dato
Melissa Mitchell
Chief Privacy Officer1.4yrsNessun datoNessun dato

3.8yrs

Durata media

44yo

Età media

Gestione esperta: Il team dirigenziale di PHR è considerato esperto (durata media dell'incarico 3.8 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Chaim Indig
Co-Founder19.8yrsUS$8.27m2.25%
$ 28.2m
Eve Kurtin
Board Observerno dataNessun datoNessun dato
Edward Cahill
Independent Director17.1yrsUS$232.46k0.065%
$ 814.8k
Michael Weintraub
Independent Chairman19.8yrsUS$384.98k0.57%
$ 7.2m
Richard Jackson
Member of Medical Advisory Boardno dataNessun datoNessun dato
Gillian Munson
Independent Director5.5yrsUS$257.46k0.018%
$ 221.3k
Elsa-Grace Giardina
Member of Medical Advisory Boardno dataNessun datoNessun dato
Mark Blais
Member of Medical Advisory Boardno dataNessun datoNessun dato
Michael Brodman
Member of Medical Advisory Boardno dataNessun datoNessun dato
Lee Schwamm
Member of Medical Advisory Boardno dataNessun datoNessun dato
Susan MacDonald
Member of Medical Advisory Boardno dataNessun datoNessun dato
Mark Smith
Independent Director6.1yrsUS$244.98k0.011%
$ 132.5k

17.1yrs

Durata media

62yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di PHR è composto da personale esperto e esperto (durata media dell'incarico 17.1 anni).